Patient Care

Some Readmission Risk Factors Not Captured by Medicare


Clinical question: Are there patient characteristics not currently measured by the Medicare readmission program that account for differences in hospital readmission rates?

Background: The Medicare Hospital Readmissions Reduction Program (HRRP) financially penalizes hospitals with higher than expected 30-day readmission rates. During 2014, more than 2,000 U.S. hospitals were fined $480 million for high readmission rates. HRRP accounts for differences in patient age, gender, discharge diagnosis, and diagnoses identified in Medicare claims over the previous 12 months; however, the impact of other factors is uncertain.

Study design: Survey data from the Health and Retirement Study, with linked Medicare claims.

Setting: Community-dwelling U.S. adults, older than 50 years.

Synopsis: Investigators analyzed more than 33,000 admissions from 2000 to 2012. They found 22 patient characteristics not included in the HRRP calculation that were statistically significantly predictive of hospital-wide, 30-day readmission and were more likely to be present among patients cared for in hospitals in the highest quintile of readmission rates. These characteristics reduced by 48% the differences in readmission rate between the highest- and lowest-performing quintiles. Examples include patient ethnicity, education level, personal as well as household income level, presence of prescription drug plan, Medicaid enrollment, cognitive status, and numerous others.

Bottom line: Patient characteristics account for much of the difference in readmission rates between high- and low-performing hospitals, suggesting that HRRP penalties reflect who hospitals treat as much as how well they treat them.

Citation: Barnett ML, Hsu J, McWilliams JM. Patient characteristics and differences in hospital readmission rates. JAMA Intern Med. 2015;175(11):1803-1812.

Short Take

Spironolactone Is a Winner in Drug-Resistant Hypertension

In patients with drug-resistant hypertension, spironolactone 25-50 mg was superior to bisoprolol 5-10 mg or doxazosin 4-8 mg. Hyperkalemia greater than 6.0 mEq/L occurred in 2% of patients.

Citation: Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment pathway for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068.

Recommended Reading

Leadership Academy ‘Hits Nail on the Head’
The Hospitalist
Team Hospitalist Advisory Board Accepting Applications for 2016-2018 Terms
The Hospitalist
Methylphenidate Linked to Sleep and Appetite Loss
The Hospitalist
Listen Now: Highlights of the December 2015 issue of The Hospitalist
The Hospitalist
Stent Thrombosis Risk Linked to Bioresorbable Scaffold
The Hospitalist
IVUS Stent Implantation Could Reduce Cardiac Events
The Hospitalist
Unassigned, Undocumented Patients Take a Toll on Healthcare and Hospitalists
The Hospitalist
Hospital Medicine Exchange Adds Mobile App to Mark Its 3rd Birthday
The Hospitalist
Heparin Bridging for Atrial Fibrillation
The Hospitalist
99% of Medical-Device Monitoring Alerts Not Actionable
The Hospitalist
   Comments ()